Citius Pharmaceuticals Advances Toward Commercialization with FDA-Approved LYMPHIR and Late-Stage Pipeline

Citius Pharmaceuticals, Inc. (NASDAQ: CTXR) is increasingly positioning itself as a commercial-stage biopharmaceutical company following the launch of its FDA-approved oncology therapy, LYMPHIR (denileukin diftitox-cxdl), and the advancement of a diversified pipeline. The company's strategic focus on first-in-class critical care products addresses significant unmet medical needs, potentially offering substantial commercial opportunities.

LYMPHIR, approved by the U.S. Food and Drug Administration in August 2024, is a targeted immunotherapy for adult patients with relapsed or refractory Stage I-III cutaneous T-cell lymphoma (CTCL) after at least one prior systemic therapy. CTCL is a rare form of non-Hodgkin lymphoma primarily affecting the skin. The drug is an engineered fusion protein combining interleukin-2 and diphtheria toxin, designed to target cells expressing IL-2 receptors. Commercial distribution began in December 2025 through Citius Oncology, Inc. (Nasdaq: CTOR), the company's oncology-focused subsidiary. During the first six months of fiscal 2026, which included four months of commercial sales, LYMPHIR generated $5.6 million in net product revenue with gross margins of approximately 80%. Payer coverage has reached nearly 100% of covered commercial lives, and 83% of targeted accounts have achieved formulary inclusion or are under active review as of May 2026. The company has also initiated international expansion with an initial shipment to Europe in April 2026 and reports repeat orders from initial accounts.

Beyond CTCL, Citius is exploring LYMPHIR in additional oncology settings. Investigator-initiated studies have evaluated LYMPHIR in combination with pembrolizumab for recurrent or refractory gynecologic cancers and prior to commercial CD19-directed CAR-T therapy in high-risk relapsed or refractory diffuse large B-cell lymphoma. Positive topline results from both Phase 1 studies were reported in fiscal 2026.

In the late-stage pipeline, Mino-Lok is an antibiotic lock solution designed to salvage central venous catheters in patients with catheter-related bloodstream infections (CRBSIs) and central line-associated bloodstream infections (CLABSIs). These infections are particularly serious in cancer and hemodialysis patients. Mino-Lok aims to eradicate infection while preserving the catheter, avoiding the risks of catheter removal and reinsertion, such as pneumothorax, arterial puncture, and catheter misplacement. There are currently no FDA-approved therapies specifically for salvaging infected central venous catheters. A completed Phase 3 pivotal superiority trial met its primary and secondary endpoints. Mino-Lok has received Qualified Infectious Disease Product (QIDP) and Fast Track designations from the FDA, and Citius holds worldwide rights through a license from The University of Texas MD Anderson Cancer Center. The company has received guidance from the FDA outlining a pathway to support a future New Drug Application submission. Investor materials estimate worldwide sales potential of approximately $1.8 billion.

Halo-Lido (CITI-002) is a proprietary topical formulation combining halobetasol and lidocaine for the symptomatic treatment of hemorrhoids. It aims to provide both anti-inflammatory and anesthetic relief. Approximately 10 million people in the U.S. report hemorrhoid symptoms annually, yet there are no FDA-approved prescription products for this indication. If approved, Halo-Lido could become the first such product. The company completed a Phase 2b study in 2023 and has met with the FDA to discuss next steps.

Citius is also developing a stem cell platform based on induced pluripotent stem cell-derived mesenchymal stem cells (i-MSCs) for acute respiratory distress syndrome (ARDS), including lung injury associated with sepsis. In a proof-of-concept sheep model, interim results showed improvements in oxygenation, systemic shock, pulmonary vascular injury, and bacterial clearance compared with controls. Additional studies with larger sample sizes are warranted to inform future human trials.

The company's leadership team brings extensive pharmaceutical experience. Leonard Mazur, Co-Founder, CEO, and Chairman, has approximately five decades in the industry, having founded Genesis Pharmaceuticals and held roles at Medicis Pharmaceutical and others. Myron Holubiak, Co-Founder and Executive Vice Chairman, previously served as president of Roche Laboratories and held multiple sales and marketing roles during a 19-year career with Roche. This experienced team supports the strategy of advancing differentiated therapies from development to commercialization.

With LYMPHIR generating commercial revenue and Mino-Lok, Halo-Lido, and the stem cell platform progressing, Citius is positioned around multiple potential catalysts. The company's focus on unmet medical needs and differentiated commercial opportunities provides several paths for future value creation. For more information, visit Citius Pharma.